These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 19486542)

  • 21. Integrated Assessment of Viral Transcription, Antigen Presentation, and CD8
    Mota TM; McCann CD; Danesh A; Huang SH; Magat DB; Ren Y; Leyre L; Bui TD; Rohwetter TM; Kovacs CM; Benko E; MacLaren L; Wimpelberg A; Cannon CM; Hardy WD; Safrit JT; Jones RB
    J Virol; 2020 Apr; 94(9):. PubMed ID: 32051267
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.
    Olesen R; Vigano S; Rasmussen TA; Søgaard OS; Ouyang Z; Buzon M; Bashirova A; Carrington M; Palmer S; Brinkmann CR; Yu XG; Østergaard L; Tolstrup M; Lichterfeld M
    J Virol; 2015 Oct; 89(20):10176-89. PubMed ID: 26223643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergistic reactivation of latent HIV-1 provirus by PKA activator dibutyryl-cAMP in combination with an HDAC inhibitor.
    Lim H; Kim KC; Son J; Shin Y; Yoon CH; Kang C; Choi BS
    Virus Res; 2017 Jan; 227():1-5. PubMed ID: 27677464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autophagy induction by histone deacetylase inhibitors inhibits HIV type 1.
    Campbell GR; Bruckman RS; Chu YL; Spector SA
    J Biol Chem; 2015 Feb; 290(8):5028-5040. PubMed ID: 25540204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The thioacetate-ω(γ-lactam carboxamide) HDAC inhibitor ST7612AA1 as HIV-1 latency reactivation agent.
    Badia R; Grau J; Riveira-Muñoz E; Ballana E; Giannini G; Esté JA
    Antiviral Res; 2015 Nov; 123():62-9. PubMed ID: 26348004
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sequential treatment with 5-aza-2'-deoxycytidine and deacetylase inhibitors reactivates HIV-1.
    Bouchat S; Delacourt N; Kula A; Darcis G; Van Driessche B; Corazza F; Gatot JS; Melard A; Vanhulle C; Kabeya K; Pardons M; Avettand-Fenoel V; Clumeck N; De Wit S; Rohr O; Rouzioux C; Van Lint C
    EMBO Mol Med; 2016 Feb; 8(2):117-38. PubMed ID: 26681773
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BI-2536 and BI-6727, dual Polo-like kinase/bromodomain inhibitors, effectively reactivate latent HIV-1.
    Gohda J; Suzuki K; Liu K; Xie X; Takeuchi H; Inoue JI; Kawaguchi Y; Ishida T
    Sci Rep; 2018 Feb; 8(1):3521. PubMed ID: 29476067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alternate NF-κB-Independent Signaling Reactivation of Latent HIV-1 Provirus.
    Acchioni C; Remoli AL; Marsili G; Acchioni M; Nardolillo I; Orsatti R; Farcomeni S; Palermo E; Perrotti E; Barreca ML; Sabatini S; Sandini S; Parolin C; Lin R; Borsetti A; Hiscott J; Sgarbanti M
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31243131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In Vitro Pharmacokinetic/Pharmacodynamic Modeling of HIV Latency Reversal by Novel HDAC Inhibitors Using an Automated Platform.
    Newhard W; Patel M; Cassaday J; Ballard J; Squadroni B; Wu G; Liu J; Yu W; Kozlowski J; Zuck P; Howell B; Hazuda D; Vargo R; Barnard R
    SLAS Discov; 2021 Jun; 26(5):642-654. PubMed ID: 33427012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combinations of Histone Deacetylase Inhibitors with Distinct Latency Reversing Agents Variably Affect HIV Reactivation and Susceptibility to NK Cell-Mediated Killing of T Cells That Exit Viral Latency.
    Covino DA; Desimio MG; Doria M
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34206330
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histone Deacetylase Inhibitors Enhance CD4 T Cell Susceptibility to NK Cell Killing but Reduce NK Cell Function.
    Pace M; Williams J; Kurioka A; Gerry AB; Jakobsen B; Klenerman P; Nwokolo N; Fox J; Fidler S; Frater J;
    PLoS Pathog; 2016 Aug; 12(8):e1005782. PubMed ID: 27529554
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
    Elliott JH; Wightman F; Solomon A; Ghneim K; Ahlers J; Cameron MJ; Smith MZ; Spelman T; McMahon J; Velayudham P; Brown G; Roney J; Watson J; Prince MH; Hoy JF; Chomont N; Fromentin R; Procopio FA; Zeidan J; Palmer S; Odevall L; Johnstone RW; Martin BP; Sinclair E; Deeks SG; Hazuda DJ; Cameron PU; Sékaly RP; Lewin SR
    PLoS Pathog; 2014 Oct; 10(10):e1004473. PubMed ID: 25393648
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Small Molecule Inhibitors of BAF; A Promising Family of Compounds in HIV-1 Latency Reversal.
    Stoszko M; De Crignis E; Rokx C; Khalid MM; Lungu C; Palstra RJ; Kan TW; Boucher C; Verbon A; Dykhuizen EC; Mahmoudi T
    EBioMedicine; 2016 Jan; 3():108-121. PubMed ID: 26870822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chidamide, a histone deacetylase inhibitor-based anticancer drug, effectively reactivates latent HIV-1 provirus.
    Yang W; Sun Z; Hua C; Wang Q; Xu W; Deng Q; Pan Y; Lu L; Jiang S
    Microbes Infect; 2018; 20(9-10):626-634. PubMed ID: 29126877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel histone deacetylase inhibitors CG05 and CG06 effectively reactivate latently infected HIV-1.
    Choi BS; Lee HS; Oh YT; Hyun YL; Ro S; Kim SS; Hong KJ
    AIDS; 2010 Feb; 24(4):609-11. PubMed ID: 20154582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV-1 reactivation induced by apicidin involves histone modification in latently infected cells.
    Lin S; Zhang Y; Ying H; Zhu H
    Curr HIV Res; 2011 Jun; 9(4):202-8. PubMed ID: 21631428
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The novel histone deacetylase inhibitors metacept-1 and metacept-3 potently increase HIV-1 transcription in latently infected cells.
    Shehu-Xhilaga M; Rhodes D; Wightman F; Liu HB; Solomon A; Saleh S; Dear AE; Cameron PU; Lewin SR
    AIDS; 2009 Sep; 23(15):2047-50. PubMed ID: 19609198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function.
    Clutton G; Xu Y; Baldoni PL; Mollan KR; Kirchherr J; Newhard W; Cox K; Kuruc JD; Kashuba A; Barnard R; Archin N; Gay CL; Hudgens MG; Margolis DM; Goonetilleke N
    Sci Rep; 2016 Aug; 6():30749. PubMed ID: 27480951
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
    Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes.
    Jones RB; O'Connor R; Mueller S; Foley M; Szeto GL; Karel D; Lichterfeld M; Kovacs C; Ostrowski MA; Trocha A; Irvine DJ; Walker BD
    PLoS Pathog; 2014 Aug; 10(8):e1004287. PubMed ID: 25122219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.